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PEETING HIGHLIGHTS
eeting Highlights of the
th Annual Scientific Sessions of the Society for
ardiovascular Magnetic Resonance, January 21 to 23, 2005
hristopher M. Kramer, MD,* Matthias G. Friedrich, MD,† Stefan Neubauer, MD,‡
atthias Stuber, PHD,§ Tal Geva, MD, Charles B. Higgins, MD,¶ Warren J. Manning, MD#
harlottesville, Virginia; Calgary, Canada; Oxford, United Kingdom; Baltimore, Maryland;
oston, Massachusetts; and San Francisco, California
Parallel tracks for clinical scientists, basic scientists, and pediatric imagers was the novel
approach taken for the highly successful 8th Annual Scientific Sessions of the Society for
Cardiovascular Magnetic Resonance, held in San Francisco, California, January 21 to 23,
2005. Attendees were immersed in information on the latest scientific advances in cardio-
vascular magnetic resonance (CMR) from mice to man and technological advances from
systems with field strengths from 0.5 T to 11.7 T. State-of-the-art applications were
reviewed, spanning a wide range from molecular imaging to predicting outcome with CMR
in large patient populations. (J Am Coll Cardiol 2005;46:411–6) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.045College of Cardiology Foundation
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Ihe 8th Annual Scientific Sessions of the Society for
ardiovascular Magnetic Resonance (SCMR) took place
anuary 21 to 23, 2005, at the Hyatt Regency Embarcadero
n San Francisco, California. Over 1,000 participants at-
ended the meeting, which offered parallel tracks for clinical
ardiovascular magnetic resonance (CMR) scientists, basic
MR scientists, and pediatric imagers, an innovative format
hat was well received. A pre-conference physician’s clinical
ntroductory workshop was attended by 319 participants, a
ecord number. A three-day concurrent CMR technologist
orkshop was likewise well attended, with 110 participants,
nd included a best abstract session. A trainees and students
our offered helpful hints for career advancement in CMR
or both basic and clinical trainees alike. An entire session
as devoted to issues surrounding training and credentialing
uidelines and reimbursement of CMR. An expanded
umber of oral abstracts were presented in the main
eeting, numbering over 110. In total, nearly 400 abstracts
ere presented, either orally or in poster form, including
wo moderated poster sessions. Keynote speakers included
alentin Fuster, MD (Mount Sinai Hospital, New York,
ew York), who spoke on “Imaging the Vulnerable Pa-
ient”; Joanne Ingwall, PhD (Brigham and Women’s Hos-
ital, Boston, Massachusetts), who delivered an address
ntitled “MR Molecular Spectroscopy”; and Kanu Chatterjee,
D (University of California, San Francisco), who led off the
From the *University of Virginia Health System, Charlottesville, Virginia; †Uni-
ersity of Alberta, Calgary, Canada; ‡Oxford University, Oxford, United Kingdom;
Johns Hopkins University, Baltimore, Maryland; Children’s Hospital, Boston,
assachusetts; ¶University of California, San Francisco, California; and the #Beth
srael-Deaconess Medial Center, Boston, Massachusetts.E
Manuscript received March 17, 2005; revised manuscript received March 22, 2005,
ccepted April 13, 2005.MR in congestive heart failure (CHF) session with an
Overview of the Problem of CHF.”
EST ABSTRACT COMPETITION
ased on the abstract submission scoring and subsequent
resentation at the meeting, a panel of reviewers selected the
wo best oral clinical science and basic science presentations,
he best pediatric oral presentation, and the two best
oderated poster presentations. In the prize-winning clin-
cal abstract, researchers from five centers showed in 100
atients the predictive value of infarct size determined in
ontrast-enhanced images (1). Among the risk factors such
s CHF symptoms, ejection fraction (EF), severity of
oronary disease, and CMR-derived infarct size, only an
nfarct size of more than 15% of left ventricular (LV) mass
nd reduced EF were independent predictors of outcome. In
multivariate analysis, CMR-derived infarct size of more
han 15% of LV mass had the highest predicted value for
eath, with a relative risk of 9.9 (95% confidence interval, 1.6
o 63). In the second-prize clinical abstract, Dr. Timothy
lbert (Duke University, Durham, North Carolina) applied
ontrast-enhanced CMR in 96 patients 4 3 days after acute
yocardial infarction (MI) and found that the prevalence of
icrovascular obstruction as defined by the presence of
ypoenhancement surrounded by hyperenhancement de-
reases over time (2). Whereas microvascular obstruction
as present in 60% of 96 patients at 1 to 2 days post-MI and
n only 27% at 8 to 14 days, none of a subgroup of 43
atients imaged at 151 days after MI had microvascular
bstruction. The top pediatric abstract was presented by Dr.
sabelle Vonder Muhll (Royal Brompton Hospital, London,
ngland) who showed that patients with successful coarc-
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Highlights of the 2005 SCMR Annual Meeting August 2, 2005:411–6ation repair and without arterial hypertension have normal
ortic pulsatile hemodynamics and normal LV mass (3).
The winning basic science oral abstract was presented by
r. Yijen Wu (Carnegie-Mellon University, Pittsburgh,
ennsylvania), who used a CMR approach to visualize
ingle immune cells in acute allograft rejection (4). The
roup used large iron-oxide particles (mean size, 0.98 m),
o-called Bangs particles, to label a rat model of working
ung and heart rejection in a high-field setting at 4.7 T and
1.7 T. A distinct pattern of punctual signal intensity
hanges was attributed to single-cell labels because the
adius of the signal intensity changes exceeded that of the
abeled cell by a factor up to 50. The runner-up oral abstract
as given by Dr. Patrick Winter (Washington University,
t. Louis, Missouri), who presented data on the use of
MR to follow up cholesterol-fed New Zealand white
abbits with early atherosclerosis after treatment with
umagillin-loaded nanoparticles (5). Using v3-targeted
aramagnetic particles as a reporter, the investigators could
ccurately monitor therapeutic success.
Dr. Vinay Pai (New York University and the National
eart, Lung, and Blood Institute) presented a prize-
inning moderated poster regarding a new approach for
MR imaging with extremely high temporal resolution (6).
he group used a modified multi-echo steady-state free
recession (SSFP) sequence combined with parallel imaging
echniques. With this approach, called phase train imaging,
temporal resolution of up to 1.5 ms could be achieved,
llowing for studies of valvular motion and ventricular
yssynchrony. Another prize-winning moderated poster
as given by Dr. Vivek Muthurangu (Kings College,
ondon, England), who used CMR flow data in a two-
lement Windkessel model to calculate pulmonary vascular
esistance without knowing the pulmonary capillary wedge
ressure (7). In 15 patients, cardiac catheterization was
erformed during the CMR study. The CMR flow data
ere obtained at baseline and after nitric oxide administra-
ion and compared with invasive measurements. The inves-
igators reported a mean difference of only 4% at baseline
nd 2% during nitric oxide. Thus, CMR-derived flow data
llow for complete non-invasive quantification of pulmo-
ary vascular resistance.
LINICAL SCIENCE
ontroversies in CMR—stress and viability. In the
pening clinical plenary session, new approaches to the
ssessment of ischemic heart disease were discussed. The
mportance of both rest imaging to identify artifacts during
rst-past perfusion imaging during vasodilator stress and
ate imaging to properly identify regions of myocardial scar
s the cause of hypoperfusion was emphasized. The com-
ined use of late gadolinium enhancement with response to
ow-dose dobutamine in a given segment was discussed as a
ew approach to assessing viability in segments with non-
ransmural chronic infarction. The latest data on optimal fitress techniques were reviewed, concluding that dobut-
mine stress function offers the best overall accuracy,
hereas vasodilator stress first-pass perfusion imaging may
e the most sensitive technique.
These issues were addressed in several abstract presenta-
ions. Quantitative first-pass perfusion magnetic resonance
as used to show reduced perfusion at rest in myocardial
egions supplied by arteries in patients with severe stenoses
80% to 100% stenoses) that improved after angioplasty (8).
 multi-center report (9) derived from the Women’s Isch-
mic Syndrome Evaluation (WISE) study in 133 women
ith suspected myocardial ischemia combined an interme-
iate Framingham score with a global myocardial perfusion
ndex derived from resting perfusion CMR to select patients
or x-ray coronary angiography. Each was independently
redictive of major adverse cardiovascular events. In a study
ombining noninvasive modalities, adenosine stress CMR
erfusion was used to assign hemodynamic significance to
tenoses identified on cardiac computed tomography (CCT)
ngiography in a subset of 68 patients in which determina-
ion of significance was equivocal because of borderline
arrowing or heavy calcification (10). Subendocardial per-
usion deficits were seen in 10 of the 68 patients in regions
eopardized by stenoses shown on CCT, suggesting a
otential complementary role of these techniques.
High-dose dobutamine stress cine MR and late gadolin-
um enhancement have both been used to effectively predict
ardiac events in patients with known obstructive coronary
rtery disease. After 16-month follow-up of 320 patients,
igh-dose dobutamine stress cine CMR predicted adverse
ardiac events (11) in a 3:1 ratio in those with to those
ithout wall motion abnormalities. Late gadolinium en-
ancement predicted event-free survival in 257 patients
ith symptomatic coronary artery disease over a mean
ollow-up period of 13.8 months (12). By multivariate Cox
egression model, the presence of late enhancement was the
trongest predictor beyond standard risk predictors.
Late gadolinium enhancement identified microvascular
bstruction in 17 of 32 patients within one week after
uccessful percutaneous interventional reperfusion of ST-
egment elevation MI (13). Microvascular obstruction was
ssociated with later reperfusion, greater transmurality of
nfarction, more compromised ventricular function, in-
reased ventricular volumes, and larger infarct mass. Two
tudies (14,15) reported the effectiveness of late gadolinium
nhancement for identifying right ventricular (RV) infarc-
ion in patients with acute inferior MI (14,15). Late
adolinium enhancement detected RV involvement in five
imes more patients with inferior MI than was clinically
uspected (15).
MR in CHF. The CMR in CHF plenary session high-
ighted the utility of CMR techniques, including volumetric
maging and late gadolinium enhancement, for identifying
he etiology of dilated cardiomyopathy and evaluating phar-
acologic, revascularization, and surgical therapies. Novel
ndings of late gadolinium enhancement in several clinical
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August 2, 2005:411–6 Highlights of the 2005 SCMR Annual Meetingcenarios were emphasized, including hypertrophic cardio-
yopathy after alcohol septal ablation, myocarditis, amy-
oidosis, and arrhythmogenic RV cardiomyopathy.
A number of abstracts regarding the use of CMR in CHF
ere presented at SCMR. Patients optimally treated with
eta-blockade and angiotensin-converting enzyme inhibi-
ion were shown not to have adverse remodeling as dem-
nstrated by CMR (16). Many of these patients with CHF
ere shown to have impaired elastic properties of the aorta
17). Regression of remote LV mass after alcohol septal
blation for hypertrophic cardiomyopathy was shown, sug-
esting some degree of afterload dependence of the hyper-
rophy (18). Late gadolinium enhancement shows myocar-
ial scarring/damage in 24% of patients with sarcoidosis
19) and in 40% of patients with beta thalassemia major
20). In the latter disease, T2* measures of iron loading were
een in 65% of 167 patients screened with a significant
elationship between T2* and EF (21). In another study,
ethods for optimizing the measurements of iron overload
ere identified (22).
MR and CCT. A special Clinical Plenary Session was
eld comparing CMR with CCT. The safety of pacemakers
nd implanted cardioverter-defibrillators in the MR envi-
onment was discussed, including historical ex-vivo data
egarding potential lead heating and pacemaker reprogram-
ing as well as provocative animal data showing safe CMR
canning with modern pacemakers. In all clinical cases, an
lectrophysiologist with pacemaker scanning tools is present
or the CMR examination. The review of CCT included a
iscussion of risks of increasing levels of ionizing radiation
xposure as well as prospective electrocardiographic gating
pproaches to reducing patient exposure levels.
These were followed by two focused applications of
MR and CCT on the pulmonary veins and coronary
maging. Data were reviewed highlighting the two modal-
ties for imaging of anomalous pulmonary venous drainage
nd follow-up imaging for patients who have undergone
ulmonary vein ablation for atrial fibrillation. A discussion
f coronary imaging followed, with impressive images
hown for both modalities in the identification of anoma-
ous coronary artery disease and native vessel integrity, and
or characterization of coronary artery bypass graft patency.
or native vessel disease, 64-slice CCT units seemed to be
articularly advantageous (vs. 16-slice CCT) with regard to
n abbreviated breath-hold and improved success for imag-
ng of distal segments. Despite the shorter breath-hold
uration, similar iodinated contrast volume is needed with
ncreased radiation exposure (vs. 16-slice CCT units).
Comparative studies between CCT and CMR in refer-
nce to the gold standard X-ray coronary angiography are
ecoming increasingly important. In one study, 16-slice
CT and a CMR protocol were compared (23). It was
ound that in segments interpretable by CCT, it offered the
uperior diagnostic accuracy when compared with CMR.
owever, calcifications posed a major challenge for thenterpretability of CCT. In a large single-center trial (24) dncluding 92 patients with suspected coronary artery disease,
whole-heart three-dimensional coronary CMR technique
ncluding parallel imaging showed outstanding image qual-
ty and a high sensitivity (85%), specificity (90%), negative
88%) and positive (88%) predictive value, and accuracy
88%) for the identification of coronary artery disease with
-ray coronary angiography as the gold standard.
ASIC SCIENCE
umen, wall, and new contrast mechanisms. Several lead-
ng figures in the field discussed the role of CMR in
dentifying the vulnerable patient by imaging atherosclerotic
laque using new contrast agents and other mechanisms to
dentify early plaque and inflammation within plaque. Mo-
ecular imaging agents are extending the potential of noninva-
ive medical diagnosis from gross anatomic descriptions to
omplicated phenotypic characterizations based on the recog-
ition of unique cell surface biochemical signatures. The MR
anoparticulate agents afford the opportunity not only for
argeted diagnostic studies but also for image-monitored
ite-specific therapeutic delivery, which will offer new clin-
cal approaches to many diseases. Atherosclerotic plaque
maging in the carotid vessels by multi-spectral CMR with
he addition of contrast agents for plaque characterization
as discussed, including use in multi-center trials of new
herapies for atherosclerosis regression and stabilization.
olecular imaging. The molecular imaging session re-
iewed several imaging approaches, including nuclear tech-
iques, CMR, and CMR spectroscopy. It was pointed out
hat sensitivity for nuclear probes is higher than that of
MR at present. Novel CMR approaches to track cellular
herapy using ultra-small particulate iron oxides (USPIO)
nd gadolinium-based nanoparticles were reviewed in detail.
An entire session of the opening day was devoted to
olecular abstracts, including discussion of new contrast
gents. A magneto-optical iron oxide agent was applied to
mage inflamed atherosclerotic plaque in apoE/ mice
25). Another group used iron particles, small paramagnetic
ron oxide particles, conjugated to vascular cell adhesion
olecule-1 antibody to identify activated endothelial cells
sing ex vivo CMR (26). An off-resonance CMR sequence
an be used to generate positive rather than negative
ontrast with USPIOs (27). A novel gadolinium-labeled
brin-targeted peptide was used to image carotid artery
hrombus in a rabbit model, showing that the targeted agent
erformed better than conventional gadolinium (28). The
ame compound was used to image left atrial thrombi in a
wine model (29). A different gadolinium-based compound,
texaphyrin complex, was shown to improve identification
f aortic atherosclerosis in a rabbit model (30). Nanopar-
icles targeted to v3 or collagen III were used to identify
laque in balloon-stretch injured carotid arteries in a swine
odel (31). Gadolinium can also be loaded with high-
ensity lipoprotein-like nanoparticles that are then taken up
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Highlights of the 2005 SCMR Annual Meeting August 2, 2005:411–6y atherosclerotic plaques that show CMR enhancement
fter 24 h (32).
ew techniques in CMR. The basic science session on
echnical advances in the field was an exciting one. Rapid
rogress is being made in interventional CMR, high-field
MR, massively parallel imaging, novel non-rectilinear
-space trajectories, spectroscopic approaches, and quanti-
ative measures of intramyocardial strain.
For cardiovascular magnetic resonance coronary angiog-
aphy (MRCA), the ease of use, near-isotropic spatial
esolution, and speed of scan times require further improve-
ent. For these reasons, a strong focus on the technical
evelopment of MRCA was seen at SCMR. The combi-
ation of most advanced 32-channel receiver technology,
oil architecture, and parallel imaging showed promise for
ubstantially abbreviated scanning times in MRCA (33).
sotropic spatial resolution and a significant improvement in
ase of use was reported for a self-navigated whole-heart
oronary MRCA technique that avoids tedious plan scan-
ing and navigator placement (34). In another study (35),
n excellent correlation between interventional MRCA
sing selective gadolinium injection and X-ray coronary
ngiography was reported in an animal model. Similarly,
xperimental in-vitro studies with polarized 13C show great
romise for selective and exclusive visualization of the
oronary arterial tree (36).
urine CMR. Genetically manipulated mouse models
lay an ever-increasing role in cardiovascular research be-
ause they allow the study of the functional effects of
eleting or augmenting a specific gene and its product in
ice; CMR is emerging as the most appropriate technique
or cardiac phenotyping because of the miniature size of the
ouse heart and its fast heart rate.
Many methodologic advances in murine CMR were on
isplay, including three-dimensional deformation analysis
f the temporal evolution of myocardial dysfunction in mice
ost-MI (37). Cardiovascular magnetic resonance with
erumoxtran-10 particles taken up by macrophages allows
ccurate assessment of inflammation accompanying myo-
ardial infarction (38). Infarct expansion using late gadolin-
um enhancement was shown, and investigators showed that
nfarct size expressed as the percent of LV mass decreased
ith time, but increased when expressed as percent of LV
ircumference (39). The first successful implementation of
n vivo 1H-MR spectroscopy in mice was reported from a
-l voxel in the interventricular septum with quantification
f metabolites such as creatine, lipids, and taurine (40).
Applications of CMR to transgenic mouse models in-
luded the use of bradykinin B2 receptor knockout and
ngiotensin-2-receptor overexpression mice to show that
ost-infarct remodeling in angiotensin-2 receptor overex-
ressed mice is not influenced by the absence of the
radykinin B2 receptor (41). Overexpression of growth
ormone in the brain was shown to lead to impaired cardiac
unction and energetics as well as depletion of myocardial
atecholamine levels (42). Attenuation of post-MI LV dilation and dysfunction was shown in inducible nitric oxide
ynthase (iNOS) knockout mice, highlighting the impor-
ant role of iNOS-derived nitric oxide in remodeling (43).
-T/interventional CMR. The state of the art in high-
eld CMR and interventional CMR was emphasized,
ncluding MR-compatible equipment needs, CMR-guided
lectrophysiologic procedures, and CMR guidance of deliv-
ry of genes and stem cells in animal models. Combined
MR and X-ray systems are being used to guide interven-
ions in congenital heart disease, including closure of atrial
eptal defects and stenting for pulmonic valve stenosis or
ortic coarctation. The potential pitfalls and artifacts as well
s the potential improvements in signal-to-noise ratio at
igher field strengths were discussed at length. At higher
eld strength, the expected improvement in the signal-to-
oise ratio may be particularly beneficial for MRCA. A
ecently completed study comparing 1.5-T and 3-T coro-
ary CMR in patients with suspected coronary artery
isease (44) showed that 1.5-T methodology could easily be
dopted at 3-T, but in-depth analysis and improvement of
ndividual sequence components is still necessary to take full
dvantage of the higher field strength.
EDIATRIC IMAGING
his year the SCMR introduced the first multi-day pro-
ram dedicated to CMR of congenital and acquired pedi-
tric heart disease. An initiative to form a Pediatric Study
roup within SCMR was approved by the SCMR Board of
rustees. Some of the unique challenges of imaging patients
ith congenital heart disease (CHD) were addressed, in-
luding CMR-guided cardiac catheterization in children,
he comparison with CCT in children with vascular anom-
lies, and the optimal method for sedation of infants and
oung children. Advances in CMR applications, in partic-
lar in subgroups of patients with CHD, were discussed,
ncluding those with bidirectional cavopulmonary anasto-
osis, functional single ventricle, repaired tetralogy of
allot, and aortic coarctation.
Two groups reported on the use of late gadolinium
nhancement in congenital heart disease, including anom-
lous origin of the left coronary artery from the pulmonary
rtery (45) and postoperative CHD (46). One group de-
cribed their initial experience with CMR in a 3-T scanner
or evaluation of CHD (47), showing improvements in
ignal-to-noise ratio and shorter acquisition times as a result
f the use of parallel imaging. On the other hand, suscep-
ibility artifacts, especially with the use of the SSFP, were
ronounced and significantly limited cine imaging in in-
ants. Good agreement between flow measurements by
MR and catheterization was shown in 17 pediatric pa-
ients who were sedated with oral chloral hydrate and
reathed freely, validating the free breathing method of
easuring flow (48). Another study found that measure-
ents of RV and LV dimensions were not significantly
ifferent when measured by real-time cine CMR (acquisi-
t
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August 2, 2005:411–6 Highlights of the 2005 SCMR Annual Meetingion time, 1 min) and by electrocardiograph-triggered
SFP (acquisition time, 10 min) (49). Interstudy repro-
ucibility of CMR evaluation of RV dimensions in 10 adult
atients with repaired tetralogy of Fallot showed a coeffi-
ient of variability of 5% for RV end-diastolic and
nd-systolic volume, ejection fraction, and mass (50). A
tudy on the effect of metallic implants on CMR’s ability to
valuate the anatomy and ventricular function in 100 pa-
ients with Fontan circulation found that metallic implants
roduced image artifacts that precluded a complete volu-
etric assessment in 20% (51).
ONCLUSIONS
he 2005 SCMR meeting brought together a wide array of
nterests in the field of SCMR, including basic scientists,
linician scientists, practitioners, technologists, nurses, and
rainees, for a highly successful meeting. The combination
f practical clinical information and cutting-edge basic
cience presented at the meeting epitomizes the very bright
uture of the field.
eprint requests and correspondence: Dr. Christopher M.
ramer, University of Virginia Health System, Departments of
edicine and Radiology, Lee Street, Box 800170, Charlottesville,
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